Aripiprazole
Atypical Antipsychotic – Dopamine System Stabilizer
Aripiprazole is an atypical (second-generation) antipsychotic medication used to treat schizophrenia, bipolar disorder, and as an add-on therapy for major depressive disorder. Unlike most antipsychotics that simply block dopamine receptors, aripiprazole acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, earning it the description of a dopamine system stabilizer. This unique mechanism of action is associated with a generally favorable side effect profile, particularly regarding metabolic effects and movement disorders. Aripiprazole is available in oral tablets, orodispersible tablets, short-acting intramuscular injection for acute agitation, and a long-acting depot injection for maintenance therapy.
Quick Facts: Aripiprazole
Key Takeaways
- Aripiprazole is a unique antipsychotic that works as a partial dopamine agonist (dopamine system stabilizer), providing a different mechanism from older antipsychotics that fully block dopamine receptors.
- It is approved for schizophrenia, acute and maintenance treatment of bipolar I disorder, and as an adjunct to antidepressants for major depressive disorder in adults.
- Aripiprazole carries a lower risk of weight gain, metabolic syndrome, and sedation compared to many other atypical antipsychotics such as olanzapine or quetiapine.
- Important safety concerns include risk of impulse control disorders (pathological gambling, compulsive eating, hypersexuality), akathisia (inner restlessness), and increased mortality in elderly patients with dementia-related psychosis.
- Never stop aripiprazole abruptly without medical guidance – your doctor will gradually taper the dose to prevent relapse or withdrawal symptoms.
What Is Aripiprazole and What Is It Used For?
Aripiprazole belongs to the class of medications known as atypical (second-generation) antipsychotics, though its unique pharmacological profile has led some experts to classify it as a third-generation antipsychotic. The medication was first approved by the United States Food and Drug Administration (FDA) in 2002 and has since become one of the most widely prescribed antipsychotics worldwide. It is listed on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its importance in global healthcare.
What sets aripiprazole apart from other antipsychotics is its mechanism of action. While most antipsychotics work by blocking dopamine D2 receptors, aripiprazole functions as a partial agonist at these receptors. This means that it activates dopamine receptors in brain areas where dopamine activity is too low (such as the prefrontal cortex, which may help with negative symptoms and cognitive deficits) while simultaneously reducing dopamine activity in areas where it is excessive (such as the mesolimbic pathway, which is thought to underlie positive psychotic symptoms). Additionally, aripiprazole is a partial agonist at serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2A receptors, further contributing to its therapeutic profile.
Aripiprazole is approved for several psychiatric indications depending on the regulatory jurisdiction. In both the European Union (EU) and the United States, its primary approved uses include:
- Schizophrenia: Treatment of schizophrenia in adults and adolescents aged 15 years and older. It is effective for both positive symptoms (hallucinations, delusions, disorganized thinking) and negative symptoms (social withdrawal, flat affect, decreased motivation).
- Bipolar I Disorder: Treatment of manic and mixed episodes in bipolar I disorder, both as monotherapy and in combination with lithium or valproate. It is also used for maintenance treatment to prevent recurrence of manic episodes.
- Major Depressive Disorder (MDD): Adjunctive treatment to antidepressants in adults who have not responded adequately to antidepressant therapy alone.
- Acute agitation: The short-acting intramuscular injection form is approved for rapid treatment of agitation associated with schizophrenia or bipolar I disorder manic episodes when oral treatment is not appropriate.
The long-acting injectable form (marketed as Abilify Maintena) provides a once-monthly depot injection option for maintenance treatment of schizophrenia, which can be particularly helpful for patients who have difficulty maintaining adherence to daily oral medication. Clinical trials have demonstrated that aripiprazole long-acting injectable significantly reduces the risk of relapse compared to placebo and provides consistent drug levels throughout the dosing interval.
Aripiprazole stabilizes dopamine signaling by acting as a partial agonist at D2 receptors. In brain regions with excessive dopamine (linked to psychosis), it reduces activity. In regions with insufficient dopamine (linked to negative symptoms and depression), it enhances activity. It also modulates serotonin pathways through partial agonism at 5-HT1A and antagonism at 5-HT2A receptors, contributing to its antidepressant and anxiolytic properties.
What Should You Know Before Taking Aripiprazole?
Before initiating treatment with aripiprazole, it is essential to have a thorough discussion with your healthcare provider about your complete medical history, current medications, and any concerns. This information helps your doctor determine whether aripiprazole is appropriate for you and what monitoring may be needed during treatment.
Contraindications
You should not take aripiprazole if you are allergic (hypersensitive) to aripiprazole or any of the inactive ingredients in the formulation. Signs of an allergic reaction may include skin rash, hives, itching, swelling of the face, lips, tongue, or throat, and difficulty breathing. If you experience any signs of a severe allergic reaction, seek emergency medical attention immediately.
Elderly patients with dementia-related psychosis treated with antipsychotic medications, including aripiprazole, are at an increased risk of death. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis. Additionally, cerebrovascular adverse events (stroke and transient ischemic attack) have been reported in elderly patients with dementia receiving aripiprazole.
Suicidal thoughts and behaviors have been reported during treatment with aripiprazole. Tell your doctor immediately if you experience thoughts of self-harm or suicide before or during treatment. Close monitoring is recommended, particularly at the start of treatment and after dose changes.
Warnings and Precautions
Before starting aripiprazole, tell your doctor if you have any of the following conditions, as they may require special monitoring or dose adjustments:
- Diabetes or high blood sugar: Aripiprazole can affect blood glucose levels. Symptoms of hyperglycemia include excessive thirst, frequent urination, increased appetite, and weakness. Patients with diabetes or risk factors for diabetes should have regular blood glucose monitoring.
- Seizures (epilepsy): Aripiprazole may lower the seizure threshold. If you have a history of seizures or conditions that increase seizure risk, your doctor may need to monitor you more closely.
- Cardiovascular disease: Including a history of heart attack, heart failure, abnormal heart rhythm, stroke, or transient ischemic attack (mini-stroke). Aripiprazole can cause orthostatic hypotension (a drop in blood pressure when standing), which may lead to dizziness, lightheadedness, or fainting.
- Blood clots or family history of blood clots: Antipsychotic medications have been associated with venous thromboembolism, including deep vein thrombosis and pulmonary embolism.
- History of gambling addiction or compulsive behaviors: Aripiprazole has been associated with impulse control disorders. See the detailed warning below.
- Involuntary muscle movements: Particularly in the face, which may indicate tardive dyskinesia, a potentially irreversible condition.
Tell your doctor if you or your family/caregiver notice that you are developing urges or cravings to behave in ways that are unusual for you. These impulse control disorders can include pathological gambling, excessive eating or spending, abnormally high sex drive, or an increase in sexual thoughts or feelings. Your doctor may need to reduce your dose or stop the medication.
Pregnancy and Breastfeeding
If you are pregnant, planning to become pregnant, or breastfeeding, discuss this with your doctor before starting aripiprazole. The decision to use aripiprazole during pregnancy involves carefully weighing the benefits of treating the mother's psychiatric condition against potential risks to the developing fetus.
Neonates exposed to antipsychotic drugs, including aripiprazole, during the third trimester of pregnancy may experience withdrawal symptoms after delivery. These can include tremor, rigid or floppy muscles, drowsiness, agitation, breathing difficulties, and feeding problems. These symptoms are typically self-limiting but may require medical monitoring. If your baby develops any of these symptoms, contact your healthcare provider.
Aripiprazole passes into breast milk. If you are receiving aripiprazole, you and your doctor should discuss whether the benefits of breastfeeding outweigh the potential risks to the infant. You should not breastfeed and take aripiprazole simultaneously without clear medical advice.
Driving and Operating Machinery
Aripiprazole may cause dizziness, drowsiness, and visual disturbances. These effects should be considered when full alertness is required, such as when driving a vehicle or operating machinery. Do not drive or use machines until you know how aripiprazole affects you personally.
How Does Aripiprazole Interact with Other Drugs?
Drug interactions with aripiprazole are primarily related to its metabolism through the cytochrome P450 enzyme system, particularly CYP2D6 and CYP3A4. Understanding these interactions is critical for safe and effective use of the medication. Additionally, combining aripiprazole with other central nervous system (CNS) active substances requires caution due to the potential for additive effects.
Major Interactions
The following interactions are clinically significant and typically require dose adjustments or avoidance:
| Interacting Drug / Class | Effect | Clinical Recommendation |
|---|---|---|
| Strong CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine) | Increase aripiprazole plasma levels significantly | Reduce aripiprazole dose to approximately half the usual dose |
| Strong CYP3A4 inhibitors (ketoconazole, itraconazole) | Increase aripiprazole plasma levels | Reduce aripiprazole dose to approximately half the usual dose |
| Strong CYP3A4 inducers (carbamazepine, rifampicin, phenytoin, phenobarbital) | Decrease aripiprazole plasma levels substantially | Consider doubling the aripiprazole dose; reduce when inducer is withdrawn |
| Antihypertensive medications | Enhanced blood pressure-lowering effect; increased risk of orthostatic hypotension | Monitor blood pressure closely; adjust doses as needed |
| Serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, St. John’s Wort) | Increased risk of serotonin syndrome | Monitor for symptoms: agitation, confusion, fever, sweating, muscle rigidity |
Other Notable Interactions
Several additional medication categories warrant awareness when used alongside aripiprazole:
- Benzodiazepines and other sedatives: Combining aripiprazole with benzodiazepines or other CNS depressants may cause increased sedation, drowsiness, and dizziness. Use only under medical supervision.
- Antiarrhythmic drugs (amiodarone, flecainide): Some antiarrhythmic medications are CYP2D6 inhibitors and may increase aripiprazole levels. They can also prolong the QT interval, requiring cardiac monitoring.
- HIV medications (efavirenz, nevirapine, protease inhibitors like ritonavir): These can either increase or decrease aripiprazole levels depending on their specific enzyme-inhibiting or enzyme-inducing properties. Dose adjustment may be necessary.
- Rifabutin (tuberculosis treatment): As a moderate CYP3A4 inducer, rifabutin may reduce aripiprazole effectiveness. Monitor treatment response carefully.
- Alcohol: Although aripiprazole does not significantly potentiate the cognitive or motor effects of alcohol in clinical studies, alcohol should still be avoided as it can worsen the underlying psychiatric condition and increase the risk of side effects such as dizziness and sedation.
Approximately 5–10% of the Caucasian population are CYP2D6 poor metabolizers, meaning they break down aripiprazole much more slowly. These individuals naturally have higher aripiprazole blood levels and may need lower starting doses. Genetic testing (pharmacogenomic testing) can help identify these patients. If you are a known CYP2D6 poor metabolizer also taking a strong CYP3A4 inhibitor, your doctor should reduce the aripiprazole dose to approximately one-quarter (25%) of the usual dose.
What Is the Correct Dosage of Aripiprazole?
Aripiprazole dosage varies depending on the condition being treated, the patient's age, and other factors such as concomitant medications and metabolizer status. All dose adjustments should be made by your prescribing physician. The information below provides general guidance based on current prescribing information from the European Medicines Agency (EMA) and the FDA.
Adults
| Indication | Starting Dose | Usual Dose Range | Maximum Dose |
|---|---|---|---|
| Schizophrenia | 10–15 mg once daily | 10–15 mg/day | 30 mg/day |
| Bipolar I Disorder (manic episodes) | 15 mg once daily | 15–30 mg/day | 30 mg/day |
| Adjunct for Major Depression | 2–5 mg/day | 2–15 mg/day | 15 mg/day |
| Acute Agitation (IM injection) | 9.75 mg (1.3 ml) single injection | 5.25–15 mg per injection | 30 mg/day (all forms combined) |
| Maintenance (Depot injection) | 400 mg IM once monthly | 300–400 mg monthly | 400 mg monthly |
Aripiprazole can be taken with or without food. The tablet should be swallowed whole with water. Orodispersible tablets should be placed on the tongue, where they will rapidly dissolve in saliva, and can then be swallowed with or without water. For the intramuscular injection form, the medication is administered by a healthcare professional into the deltoid or gluteal muscle.
Children and Adolescents
Adolescents (13–17 years) – Schizophrenia
Starting dose: 2 mg/day for 2 days, then 5 mg/day for 2 days, then target dose of 10 mg/day. Maximum: 30 mg/day. Use with caution; the intramuscular injection form is not recommended for patients under 18 years.
Children (10–17 years) – Bipolar I Disorder
Starting dose: 2 mg/day for 2 days, then 5 mg/day for 2 days, then target dose of 10 mg/day. Maximum: 30 mg/day. Treatment should be supervised by a specialist in child and adolescent psychiatry.
Aripiprazole is generally not recommended for children under 13 years for schizophrenia or under 10 years for bipolar disorder, as safety and efficacy have not been established in these younger age groups.
Elderly Patients
No routine dose adjustment is required for elderly patients with schizophrenia or bipolar disorder. However, elderly patients may be more susceptible to certain side effects, particularly orthostatic hypotension (dizziness upon standing), sedation, and falls. Lower starting doses and slower titration may be advisable. As noted in the warnings section, aripiprazole is not approved for elderly patients with dementia-related psychosis due to increased risk of death and cerebrovascular events.
Missed Dose
If you miss a dose of oral aripiprazole, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and take the next one at the usual time. Do not take a double dose to make up for a forgotten one. Because aripiprazole has a long half-life (approximately 75 hours), missing a single dose is unlikely to cause significant fluctuations in blood levels, but consistent daily dosing is important for optimal treatment.
If you miss a scheduled long-acting depot injection, contact your healthcare provider as soon as possible to arrange a new appointment. The timing of your next injection may need to be adjusted depending on how long it has been since your missed dose.
Overdose
If you suspect an overdose of aripiprazole, contact your local emergency services or poison control center immediately. Symptoms of overdose may include: rapid heartbeat, agitation or aggression, speech difficulties, unusual movements (especially of the face or tongue), reduced consciousness, acute confusion, seizures, coma, fever, rapid breathing, sweating, muscle rigidity, drowsiness, slow breathing, choking sensation, high or low blood pressure, and abnormal heart rhythm.
There is no specific antidote for aripiprazole overdose. Treatment is supportive, with close monitoring of vital signs, cardiac function, and airway management as needed. In clinical overdose reports, most patients recovered with supportive care. Activated charcoal may be considered within the first hour after ingestion if the patient is alert and can protect their airway.
What Are the Side Effects of Aripiprazole?
Like all medications, aripiprazole can cause side effects, although not everyone will experience them. The side effect profile of aripiprazole is generally considered more favorable than many other atypical antipsychotics, particularly regarding metabolic effects (weight gain, cholesterol, blood sugar), sedation, and prolactin elevation. However, aripiprazole has a somewhat higher incidence of akathisia (a distressing feeling of inner restlessness and need to move) compared to some other antipsychotics.
The following side effects are organized by frequency based on clinical trial data and post-marketing surveillance reported by the European Medicines Agency and the FDA:
Common
May affect up to 1 in 10 people
- Akathisia (inner restlessness, inability to sit still)
- Extrapyramidal symptoms (tremor, involuntary twitching or twisting movements)
- Insomnia and sleep disturbances
- Anxiety and restlessness
- Headache
- Dizziness and lightheadedness
- Drowsiness and fatigue
- Nausea and vomiting
- Constipation
- Indigestion (dyspepsia)
- Excessive salivation
- Blurred vision
- Feeling of tiredness
Uncommon
May affect up to 1 in 100 people
- Elevated or reduced prolactin levels
- High blood sugar (hyperglycemia)
- Depression
- Altered or increased sexual interest
- Tardive dyskinesia (uncontrollable movements of mouth, tongue, arms and legs)
- Dystonia (sustained muscle contractions causing twisting postures)
- Restless legs syndrome
- Double vision
- Photosensitivity (light-sensitive eyes)
- Tachycardia (rapid heartbeat)
- Orthostatic hypotension (dizziness when standing up)
- Hiccups
- Dry mouth
- Diabetes mellitus
Rare or Frequency Not Known
Reported in post-marketing surveillance
- Neuroleptic malignant syndrome (NMS): fever, muscle rigidity, rapid breathing, sweating, altered consciousness, sudden changes in blood pressure and heart rate
- Serotonin syndrome: euphoria, drowsiness, clumsiness, restlessness, feeling intoxicated, fever, sweating, rigid muscles
- Seizures (convulsions)
- Severe allergic reactions including DRESS syndrome and anaphylaxis
- Venous thromboembolism (blood clots in legs or lungs)
- Rhabdomyolysis (abnormal muscle breakdown potentially causing kidney problems)
- Hepatitis and liver failure
- Pancreatitis
- Suicidal thoughts and suicide attempts
- Impulse control disorders: pathological gambling, compulsive eating, compulsive shopping, hypersexuality
- Speech disturbances
- Sudden unexplained death
- Life-threatening irregular heart rhythm
- Heart attack
- Low white blood cell count (leukopenia)
- Low platelet count (thrombocytopenia)
- Aspiration pneumonia
- Difficulty swallowing (dysphagia)
- Hair loss (alopecia)
- Excessive sweating
Contact your doctor or emergency services immediately if you experience: high fever with muscle stiffness, sweating, and altered consciousness (signs of neuroleptic malignant syndrome); uncontrollable muscle movements especially of the face or tongue (signs of tardive dyskinesia); chest pain and difficulty breathing (possible blood clot); severe allergic reaction with swelling of face, lips, or throat; or thoughts of self-harm.
In elderly patients with dementia, an increased number of deaths and cerebrovascular events (stroke, transient ischemic attack) have been reported with aripiprazole use. This is consistent with findings across all atypical antipsychotics and is the basis for the black box warning against using these medications in this population.
It is important to report any suspected side effects to your healthcare provider. Ongoing pharmacovigilance allows continuous monitoring of the benefit-risk balance of medications after they have been approved for use.
How Should You Store Aripiprazole?
Proper storage of aripiprazole is important to maintain the medication's effectiveness and safety. The storage requirements differ depending on the formulation:
- Oral tablets and orodispersible tablets: Store at room temperature, below 30°C (86°F). Keep the tablets in their original blister pack or container to protect from light and moisture. Do not remove tablets from the blister until you are ready to take them.
- Solution for injection (short-acting): Store the vial in its original carton to protect from light. The solution is light-sensitive. Do not freeze. Once opened, any unused portion should be discarded.
- Prolonged-release depot injection (Abilify Maintena): Store according to the specific manufacturer's instructions, typically at room temperature. The reconstituted suspension should be used within the timeframe specified in the product information.
Always check the expiry date on the packaging before use. The expiry date refers to the last day of the stated month. Do not dispose of medications via household waste or drain. Return unused or expired medications to a pharmacy for proper disposal to protect the environment.
What Does Aripiprazole Contain?
Aripiprazole formulations contain the active substance aripiprazole along with various inactive ingredients (excipients) that are necessary for the manufacture, stability, and delivery of the medication. The specific excipients vary depending on the formulation and manufacturer.
Oral Tablets
Aripiprazole tablets typically contain the following inactive ingredients: lactose monohydrate, corn starch (maize starch), microcrystalline cellulose, hydroxypropylcellulose, and magnesium stearate. Some formulations may also contain iron oxide pigments for coloring. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take tablets containing lactose.
Orodispersible Tablets
Orodispersible (orally disintegrating) tablets are designed to dissolve rapidly on the tongue. They typically contain excipients such as aspartame, calcium silicate, crospovidone, croscarmellose sodium, xylitol, microcrystalline cellulose, magnesium stearate, and flavoring agents. Patients with phenylketonuria should note that aspartame is a source of phenylalanine.
Solution for Injection
The injectable solution contains aripiprazole at a concentration of 7.5 mg/ml. Excipients include sulfobutylether beta-cyclodextrin (SBECD), tartaric acid, sodium hydroxide, and water for injections. This formulation contains less than 1 mmol (23 mg) of sodium per dose unit, meaning it is essentially sodium-free. The solution is a clear, colorless aqueous preparation supplied in single-use glass vials.
Frequently Asked Questions About Aripiprazole
The onset of aripiprazole's effects depends on the formulation and the condition being treated. For the intramuscular injection used in acute agitation, effects can begin within 45 to 60 minutes. For oral treatment of schizophrenia or bipolar disorder, some patients may notice improvement within the first 1 to 2 weeks, but full therapeutic benefit typically develops over 4 to 6 weeks of consistent daily use. For adjunct treatment of depression, improvement may be seen within 1 to 2 weeks. It is important not to stop treatment prematurely even if you do not notice immediate improvement, as the full benefit takes time to develop.
Aripiprazole is generally considered one of the most weight-neutral atypical antipsychotics. In clinical trials, the mean weight change with aripiprazole was minimal compared to significant weight gain seen with agents like olanzapine, quetiapine, or clozapine. However, individual responses vary, and some patients may still experience weight gain, particularly with long-term use. The CATIE trial and other comparative studies consistently rank aripiprazole among the lowest-risk antipsychotics for metabolic side effects. Regular weight monitoring and adoption of a healthy lifestyle are still recommended during treatment.
Alcohol should be avoided while taking aripiprazole. Although clinical studies suggest that aripiprazole does not significantly enhance the cognitive and motor effects of ethanol, combining alcohol with any psychiatric medication is generally inadvisable. Alcohol can worsen the psychiatric condition being treated, increase the risk of side effects such as drowsiness and dizziness, and potentially interfere with treatment effectiveness. Discuss your alcohol consumption with your doctor.
Yes, aripiprazole has been associated with impulse control disorders, including pathological gambling, compulsive eating, compulsive shopping, and hypersexuality. This is thought to be related to its partial dopamine agonist mechanism, which may stimulate reward pathways in susceptible individuals. The EMA issued a safety warning about this risk, and it is now included in the product information. If you or your caregivers notice any unusual urges or behaviors, report them to your doctor immediately. Dose reduction or discontinuation typically resolves these behaviors.
Aripiprazole use during pregnancy requires careful medical supervision. While there is no definitive evidence of teratogenicity in humans, animal studies have shown some developmental effects. The main concern is neonatal withdrawal symptoms when the medication is used during the third trimester: these can include tremor, muscle rigidity or floppiness, drowsiness, agitation, breathing difficulties, and feeding problems. These effects are usually self-limiting. The decision to continue or stop aripiprazole during pregnancy must weigh the risks of medication exposure against the risks of untreated psychiatric illness, which can also adversely affect both mother and baby. Never stop aripiprazole abruptly without consulting your doctor.
Do not stop taking aripiprazole without consulting your doctor first, even if you feel well. Stopping the medication abruptly can lead to withdrawal symptoms or a relapse of the underlying condition (schizophrenia, bipolar disorder, or depression). Your doctor will typically recommend a gradual dose reduction over a period of weeks. The pace of tapering depends on your individual circumstances, including the duration of treatment, current dose, and the condition being treated. If you are receiving the long-acting depot injection, your doctor will plan the transition carefully to ensure continuous treatment coverage.
References
- European Medicines Agency (EMA). Abilify – Summary of Product Characteristics. Last updated 2025. Available at: www.ema.europa.eu/en/medicines/human/EPAR/abilify
- U.S. Food and Drug Administration (FDA). Abilify (aripiprazole) Prescribing Information. Reference ID: 4867876. Available at: www.accessdata.fda.gov
- World Health Organization (WHO). Model List of Essential Medicines, 23rd List (2023). Geneva: WHO; 2023.
- National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. Clinical guideline CG178. Updated 2024.
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. doi:10.1016/S0140-6736(13)60733-3
- Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia (CATIE). N Engl J Med. 2005;353(12):1209-1223. doi:10.1056/NEJMoa051688
- Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat. 2006;2(4):427-443.
- De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114-126. doi:10.1038/nrendo.2011.156
- European Medicines Agency (EMA). PRAC assessment report: Aripiprazole – Impulse control disorders. EMA/165578/2016. Available at: www.ema.europa.eu
- British National Formulary (BNF). Aripiprazole. NICE Evidence Services. Updated 2025. Available at: bnf.nice.org.uk/drugs/aripiprazole
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Psychiatry and Clinical Pharmacology with documented academic background and clinical experience.
Medical Review
iMedic Medical Review Board – Independent panel of physicians who verify medical accuracy, evidence quality, and adherence to international guidelines (WHO, EMA, FDA, NICE, BNF).
Evidence Standard
Level 1A evidence based on systematic reviews, meta-analyses, and randomized controlled trials. GRADE evidence framework applied. No commercial funding.
Accessibility
Content reviewed for WCAG 2.2 Level AAA compliance. Optimized for screen readers, keyboard navigation, and assistive technology. High contrast support enabled.
Disclaimer: This article is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.